Annual CFO
-$76.38 M
+$11.18 M+12.77%
31 December 2023
Summary:
UroGen Pharma annual cash flow from operations is currently -$76.38 million, with the most recent change of +$11.18 million (+12.77%) on 31 December 2023. During the last 3 years, it has risen by +$29.51 million (+27.87%). URGN annual CFO is now -1923.25% below its all-time high of $4.19 million, reached on 31 December 2016.URGN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$27.66 M
-$3.92 M-16.49%
30 September 2024
Summary:
UroGen Pharma quarterly cash flow from operations is currently -$27.66 million, with the most recent change of -$3.92 million (-16.49%) on 30 September 2024. Over the past year, it has dropped by -$10.37 million (-59.92%). URGN quarterly CFO is now -1165.23% below its all-time high of $2.60 million, reached on 30 September 2017.URGN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$96.14 M
-$10.37 M-12.08%
30 September 2024
Summary:
UroGen Pharma TTM cash flow from operations is currently -$96.14 million, with the most recent change of -$10.37 million (-12.08%) on 30 September 2024. Over the past year, it has dropped by -$11.01 million (-12.93%). URGN TTM CFO is now -3402.48% below its all-time high of -$2.75 million, reached on 31 March 2017.URGN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
URGN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.8% | -59.9% | -12.9% |
| 3 y3 years | +27.9% | -49.7% | -11.7% |
| 5 y5 years | -104.6% | -120.8% | -73.8% |
URGN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +27.9% | -112.9% | +12.8% | -25.9% | at low |
| 5 y | 5 years | -104.6% | +27.9% | -120.8% | +22.4% | -73.8% | +13.1% |
| alltime | all time | -1923.3% | +27.9% | -1165.2% | +22.4% | -3402.5% | +13.1% |
UroGen Pharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.66 M(+16.5%) | -$96.14 M(+12.1%) |
| June 2024 | - | -$23.75 M(-25.2%) | -$85.78 M(+4.2%) |
| Mar 2024 | - | -$31.73 M(+144.2%) | -$82.30 M(+7.8%) |
| Dec 2023 | -$76.38 M(-12.8%) | -$13.00 M(-24.9%) | -$76.38 M(-10.3%) |
| Sept 2023 | - | -$17.30 M(-14.7%) | -$85.13 M(-0.4%) |
| June 2023 | - | -$20.27 M(-21.4%) | -$85.44 M(-4.4%) |
| Mar 2023 | - | -$25.81 M(+18.6%) | -$89.37 M(+2.1%) |
| Dec 2022 | -$87.56 M(+3.1%) | -$21.75 M(+23.5%) | -$87.56 M(+2.0%) |
| Sept 2022 | - | -$17.61 M(-27.2%) | -$85.88 M(-1.0%) |
| June 2022 | - | -$24.20 M(+0.8%) | -$86.74 M(+6.4%) |
| Mar 2022 | - | -$24.00 M(+19.6%) | -$81.49 M(-4.0%) |
| Dec 2021 | -$84.89 M(-19.8%) | -$20.07 M(+8.6%) | -$84.89 M(-1.4%) |
| Sept 2021 | - | -$18.48 M(-2.5%) | -$86.06 M(-7.1%) |
| June 2021 | - | -$18.95 M(-30.9%) | -$92.67 M(-5.1%) |
| Mar 2021 | - | -$27.40 M(+29.0%) | -$97.65 M(-7.8%) |
| Dec 2020 | -$105.89 M | -$21.24 M(-15.3%) | -$105.89 M(-4.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$25.08 M(+4.8%) | -$110.64 M(+12.8%) |
| June 2020 | - | -$23.93 M(-32.8%) | -$98.09 M(+10.6%) |
| Mar 2020 | - | -$35.63 M(+37.1%) | -$88.72 M(+24.9%) |
| Dec 2019 | -$71.02 M(+90.2%) | -$26.00 M(+107.5%) | -$71.02 M(+28.4%) |
| Sept 2019 | - | -$12.53 M(-13.9%) | -$55.30 M(+6.2%) |
| June 2019 | - | -$14.55 M(-18.8%) | -$52.05 M(+14.0%) |
| Mar 2019 | - | -$17.93 M(+74.4%) | -$45.64 M(+22.3%) |
| Dec 2018 | -$37.33 M(+290.2%) | -$10.28 M(+10.8%) | -$37.33 M(+13.1%) |
| Sept 2018 | - | -$9.28 M(+13.9%) | -$33.01 M(+56.2%) |
| June 2018 | - | -$8.15 M(-15.3%) | -$21.13 M(+28.5%) |
| Mar 2018 | - | -$9.62 M(+61.5%) | -$16.45 M(+71.9%) |
| Dec 2017 | -$9.57 M(-328.4%) | -$5.96 M(-329.5%) | -$9.57 M(+165.1%) |
| Sept 2017 | - | $2.60 M(-175.0%) | -$3.61 M(-41.8%) |
| June 2017 | - | -$3.46 M(+26.1%) | -$6.21 M(+126.1%) |
| Mar 2017 | - | -$2.75 M | -$2.75 M |
| Dec 2016 | $4.19 M(-158.4%) | - | - |
| Dec 2015 | -$7.17 M | - | - |
FAQ
- What is UroGen Pharma annual cash flow from operations?
- What is the all time high annual CFO for UroGen Pharma?
- What is UroGen Pharma annual CFO year-on-year change?
- What is UroGen Pharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for UroGen Pharma?
- What is UroGen Pharma quarterly CFO year-on-year change?
- What is UroGen Pharma TTM cash flow from operations?
- What is the all time high TTM CFO for UroGen Pharma?
- What is UroGen Pharma TTM CFO year-on-year change?
What is UroGen Pharma annual cash flow from operations?
The current annual CFO of URGN is -$76.38 M
What is the all time high annual CFO for UroGen Pharma?
UroGen Pharma all-time high annual cash flow from operations is $4.19 M
What is UroGen Pharma annual CFO year-on-year change?
Over the past year, URGN annual cash flow from operations has changed by +$11.18 M (+12.77%)
What is UroGen Pharma quarterly cash flow from operations?
The current quarterly CFO of URGN is -$27.66 M
What is the all time high quarterly CFO for UroGen Pharma?
UroGen Pharma all-time high quarterly cash flow from operations is $2.60 M
What is UroGen Pharma quarterly CFO year-on-year change?
Over the past year, URGN quarterly cash flow from operations has changed by -$10.37 M (-59.92%)
What is UroGen Pharma TTM cash flow from operations?
The current TTM CFO of URGN is -$96.14 M
What is the all time high TTM CFO for UroGen Pharma?
UroGen Pharma all-time high TTM cash flow from operations is -$2.75 M
What is UroGen Pharma TTM CFO year-on-year change?
Over the past year, URGN TTM cash flow from operations has changed by -$11.01 M (-12.93%)